Cannabinoids do not reduce objective measurements in muscle spasticity, but people with multiple sclerosis perceive some benefit - 24/08/11
Abstract |
Question |
Do cannabinoids have a beneficial effect on muscle spasticity and other symptoms associated with multiple sclerosis?
Study Design |
Double-blind randomised placebo controlled trial.
Main Results |
At 15 weeks, neither cannabis extract nor Δ9-tetrahydrocannabinol (THC) reduced muscle spasticity, compared with placebo (mean difference in Ashworth score: cannabis extract vs. placebo 0.32, 95% CI −1.04 to 1.67; THC vs. placebo 0.94, 95% CI −0.44 to 2.31). Participants taking cannabinoids reported improvements in mobility, pain, sleep quality, spasms and spasticity, but not irritability, depression, tiredness, tremor or energy (see Table 1).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Authors’ Conclusions |
Although cannabinoids are not beneficial for treating spasticity measured by the Ashworth score, they are useful for treating other symptoms of multiple sclerosis.
Le texte complet de cet article est disponible en PDF.Keywords : Multiple sclerosis, Cannabinoid, Spasticity, Randomised controlled trial
Plan
 | Abstracted from: Zajicek J, Fox P, Sanders H et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526. |
Vol 8 - N° 3
P. 159-161 - juin 2004 Retour au numéro
Article précédent
- Addition of artesunate to standard antimalarial drugs reduces treatment failure
- Timothy ME Davis
- Magnesium sulphate given before birth does not significantly reduce death or cerebral palsy in premature babies, but may improve motor dysfunction
- Alistair Jan Gunn, Laura Bennet
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?